About: Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season
Creator	Bunnell, Rebecca Boulton, Matthew Kent, Charlotte Redfield, Robert Daniel, Jonathan Fielding, David Bonds, Michelle Brooks, Carolyn Butler, Virginia Caine, Katherine Doan, Quang Fleming, William Greenspan, Arlene Halperin, Jewel Jones, Timothy King, Phyllis Leahy, Maureen Ma, Jay Martinroe, Julia Mullen, Jeff Niederdeppe, Patricia Quinlisk, Patrick Remington, Carlos Roig, William Schaffner, Morgan Spriggs, Stephen Starr, Terraye Swanson, Yang, Moua Yang, Tong
Source	Medline; PMC
abstract	This report updates the 2019–20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Most influenza vaccines available for the 2020–21 season will be quadrivalent, with the exception of MF59-adjuvanted IIV, which is expected to be available in both quadrivalent and trivalent formulations. Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 23, 2019; February 26, 2020; and June 24, 2020. Primary updates to this report include the following two items. First, the composition of 2020–21 U.S. influenza vaccines includes updates to the influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B/Victoria lineage components. Second, recent licensures of two new influenza vaccines, Fluzone High-Dose Quadrivalent and Fluad Quadrivalent, are discussed. Both new vaccines are licensed for persons aged ≥65 years. Additional changes include updated discussion of contraindications and precautions to influenza vaccination and the accompanying Table, updated discussion concerning use of LAIV4 in the setting of influenza antiviral medication use, and updated recommendations concerning vaccination of persons with egg allergy who receive either cell culture–based IIV4 (ccIIV4) or RIV4. The 2020–21 influenza season will coincide with the continued or recurrent circulation of SARS-CoV-2 (the novel coronavirus associated with coronavirus disease 2019 [COVID-19]). Influenza vaccination of persons aged ≥6 months to reduce prevalence of illness caused by influenza will reduce symptoms that might be confused with those of COVID-19. Prevention of and reduction in the severity of influenza illness and reduction of outpatient illnesses, hospitalizations, and intensive care unit admissions through influenza vaccination also could alleviate stress on the U.S. health care system. Guidance for vaccine planning during the pandemic is available at https://www.cdc.gov/vaccines/pandemic-guidance/index.html. This report focuses on recommendations for the use of vaccines for the prevention and control of seasonal influenza during the 2020–21 season in the United States. A brief summary of the recommendations and a link to the most recent Background Document containing additional information are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration (FDA)–licensed indications. Updates and other information are available from CDC’s influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check this site periodically for additional information.
has issue date	2020-08-21(xsd:dateTime)
bibo:doi	10.15585/mmwr.rr6908a1
bibo:pmid	32820746
has license	cc-by
sha1sum (hex)	6a8c151bf8c0392f377b214c1a3dc35b642bea69
schema:url	https://doi.org/10.15585/mmwr.rr6908a1
resource representing a document's title	Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season
has PubMed Central identifier	PMC7439976
has PubMed identifier	32820746
schema:publication	MMWR Recomm Rep
resource representing a document's body	covid:6a8c151bf8c0392f377b214c1a3dc35b642bea69#body_text
is schema:about of	named entity 'Weekly' named entity 'CDC' named entity 'Season' named entity 'Mortality' named entity 'MMWR' named entity 'Advisory Committee' named entity 'Production' named entity 'Seasonal' named entity 'Adoption' named entity 'Disease Control' named entity 'ACIP' named entity 'Influenza Season' named entity 'MMWR' named entity 'Prevention and Control' named entity 'MMWR' named entity 'MMWR' named entity 'randomized trial' named entity 'seasonal influenza' named entity 'anaphylactic reactions' named entity 'asthma' named entity 'influenza vaccine' named entity 'immunogenicity' named entity 'inactivated vaccine' named entity 'medical record' named entity 'vaccination' named entity 'Vaccine' named entity 'pertussis' named entity 'seroconversion' named entity 'Southern Hemisphere' named entity 'allergic' named entity 'coronavirus' named entity 'influenza' named entity 'adjuvants' named entity 'older adults' named entity 'medical intervention' named entity 'influenza' named entity 'influenza vaccine' named entity 'antibody' named entity 'Fluzone' named entity 'systemic reactions' named entity 'influenza' named entity 'Shingrix' named entity 'influenza vaccine' named entity 'influenza' named entity 'randomized controlled trial' named entity 'tropics' named entity 'Fluzone Quadrivalent' named entity 'SARS-CoV-2' named entity 'vaccination' named entity 'clinically significant' named entity 'influenza vaccines' named entity 'influenza'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software